Related Experiment Video
Updated: Aug 1, 2026

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
Published on: March 8, 2019
MiR-34a-3p suppresses pulmonary vascular proliferation in acute pulmonary embolism rat by targeting DUSP1
Yang Li1, Jinyan Shao1, Jianfeng Song1
1Department of Emergency, Minhang Hospital, Fudan University, Shanghai, China.
Background:
Acute pulmonary embolism (APE) is a prevalent reason of cardiovascular morbidity and mortality. Recent studies have underscored the positive effects of microRNAs (miRNAs) on many diseases. The present study aimed to identify the critical miRNA with differential expressions and explore its role in APE.
Methods:
The critical miRNA with its target gene was screened by bioinformatics analysis. Their binding relationship was analyzed by TargetScan, Dual-luciferase reporter and RNA pull-down assays. A rat model of APE was established by self-blood coagulum. Human pulmonary artery smooth muscle cells (PASMCs) were exposed to platelet-derived growth factor (PDGF-BB) for excessive proliferation, and transfected with miR-34a-3p mimic. Mean pulmonary arterial pressure (mPAP) of rat was measured, and the pulmonary tissues were used for the pathological observation by Hematoxylin-Eosin (H&E) staining. Cell viability and proliferation were detected by Cell Counting Kit-8 (CCK-8) and EdU assays. The expressions of miR-34a-3p with its target genes (including dual-specificity phosphatase-1 (DUSP1)), neuron-derived orphan receptor-1 (NOR-1) and proliferating cell nuclear antigen (PCNA) were determined by quantitative reverse transcription polymerase chain reaction (RT-qPCR) or/and Western blot.
Results:
MiR-34a-3p expression was down-regulated in APE patients, which attenuated the increment of mPAP and thickening of the pulmonary arterial walls in APE rats, accompanied with regulation of NOR-1 and PCNA levels. MiR-34a-3p suppressed DUSP1 expression by directly binding to its 3'-untranslated region (UTR), and attenuated cell viability, proliferation, and the expressions of NOR-1 and PCNA in PDGF-BB-induced PASMCs by inhibiting DUSP1 expression.
Conclusion:
Up-regulated miR-34a-3p negatively regulates DUSP1 expression to inhibit PASMC proliferation, which, thus, may act on APE treatment by negatively regulating pulmonary vascular proliferation.
Insights
This study reveals that miR-34a-3p is downregulated in acute pulmonary embolism (APE). Upregulating miR-34a-3p may treat APE by inhibiting pulmonary vascular proliferation.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Pulmonary Medicine
Background:
- Acute pulmonary embolism (APE) significantly contributes to cardiovascular morbidity and mortality.
- MicroRNAs (miRNAs) play crucial roles in various disease processes.
- Identifying key miRNAs in APE is essential for understanding its pathogenesis.
Purpose of the Study:
- To identify differentially expressed miRNAs in APE.
- To investigate the functional role of a critical miRNA in APE.
- To explore the therapeutic potential of targeting this miRNA.
Main Methods:
- Bioinformatics analysis to screen for critical miRNAs and target genes.
- In vitro assays (dual-luciferase, RNA pull-down) to confirm binding.
- Establishment of a rat model of APE and PDGF-BB-induced human pulmonary artery smooth muscle cells (PASMCs).
- Assessment of pulmonary arterial pressure, histological changes, and cell proliferation.
- Quantitative reverse transcription polymerase chain reaction (RT-qPCR) and Western blot to determine gene and miRNA expression.
Main Results:
- MiR-34a-3p expression was found to be downregulated in APE patients and rats.
- Upregulation of miR-34a-3p attenuated pulmonary hypertension and arterial wall thickening in APE rats.
- MiR-34a-3p directly suppressed DUSP1 expression, inhibiting PASMC proliferation.
- Downregulation of miR-34a-3p was associated with increased NOR-1 and PCNA levels.
Conclusions:
- Upregulated miR-34a-3p negatively regulates DUSP1 expression.
- Inhibition of PASMC proliferation by miR-34a-3p may offer a therapeutic strategy for APE.
- Targeting miR-34a-3p could be a novel approach for treating APE by modulating pulmonary vascular proliferation.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

